3pfv
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='3pfv' size='340' side='right'caption='[[3pfv]], [[Resolution|resolution]] 2.27Å' scene=''> | <StructureSection load='3pfv' size='340' side='right'caption='[[3pfv]], [[Resolution|resolution]] 2.27Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3pfv]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[3pfv]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PFV OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3PFV FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene>, <scene name='pdbligand= | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.27Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |
- | + | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3pfv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pfv OCA], [https://pdbe.org/3pfv PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3pfv RCSB], [https://www.ebi.ac.uk/pdbsum/3pfv PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3pfv ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3pfv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pfv OCA], [https://pdbe.org/3pfv PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3pfv RCSB], [https://www.ebi.ac.uk/pdbsum/3pfv PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3pfv ProSAT]</span></td></tr> | ||
</table> | </table> | ||
- | == Disease == | ||
- | [[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN]] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. | ||
== Function == | == Function == | ||
- | + | [https://www.uniprot.org/uniprot/CBLB_HUMAN CBLB_HUMAN] E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. May also be involved in EGFR ubiquitination and internalization.<ref>PMID:10022120</ref> <ref>PMID:10086340</ref> <ref>PMID:11087752</ref> <ref>PMID:11526404</ref> | |
==See Also== | ==See Also== | ||
Line 20: | Line 17: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Homo sapiens]] |
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Arrowsmith | + | [[Category: Arrowsmith CH]] |
- | [[Category: Ayinampudi | + | [[Category: Ayinampudi V]] |
- | [[Category: Bountra | + | [[Category: Bountra C]] |
- | [[Category: Bullock | + | [[Category: Bullock A]] |
- | [[Category: Canning | + | [[Category: Canning P]] |
- | [[Category: Chaikuad | + | [[Category: Chaikuad A]] |
- | [[Category: Cooper | + | [[Category: Cooper CDO]] |
- | + | [[Category: Edwards AM]] | |
- | [[Category: Edwards | + | [[Category: Gileadi O]] |
- | [[Category: Gileadi | + | [[Category: Guo K]] |
- | [[Category: Guo | + | [[Category: Krojer T]] |
- | [[Category: Krojer | + | [[Category: Muniz JRC]] |
- | [[Category: Muniz | + | [[Category: Vollmar M]] |
- | + | [[Category: Weigelt J]] | |
- | [[Category: Vollmar | + | [[Category: Von Delft F]] |
- | [[Category: Weigelt | + | |
- | [[Category: | + | |
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 peptide
|
Categories: Homo sapiens | Large Structures | Arrowsmith CH | Ayinampudi V | Bountra C | Bullock A | Canning P | Chaikuad A | Cooper CDO | Edwards AM | Gileadi O | Guo K | Krojer T | Muniz JRC | Vollmar M | Weigelt J | Von Delft F